Reuters logo
in 4 months
BRIEF-Tasly Pharmaceutical group's sub-subsidiary to invest in Shanghai bio-tech firm after merged by unit
March 24, 2017 / 11:40 AM / in 4 months

BRIEF-Tasly Pharmaceutical group's sub-subsidiary to invest in Shanghai bio-tech firm after merged by unit

1 Min Read

March 24 (Reuters) - Tasly Pharmaceutical Group Co Ltd :

* Says Tianjin-based firm Genexine, in which co's unit owns 33.34 percent stake, signed cooperation framework agreement to merge a Shanghai-based bio-tech firm

* Says the Shanghai-based bio-tech firm will be wholly owned by Tianjin-based firm Genexine

* Says co's bio-tech sub-subsidiary and CBC Investment I-Mab Limited will boost capital of $38.3 million and $111.8 million to the merged entity respectively

Source text in Chinese: goo.gl/50bKsk

Further company coverage: (Beijing Headline News)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below